The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Late toxicities in non-Hodgkin lymphoma and why they should be studied
In this video, Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, highlights the importance of understanding late toxicities in non-Hodgkin lymphoma, mentioning both aggressive and indolent lymphomas, as well as chronic lymphocytic leukemia (CLL). Dr LaCasce discusses a variety of available therapies, including CAR-T and antibody conjugates such as polatuzumab vedotin and brentuximab vedotin. Dr LaCasce also draws focus on treatment-associated toxicities that may arise, such as cognitive dysfunction, cardiac toxicities, and peripheral neuropathies. To conclude, Dr LaCasce emphasizes the importance of further studying these toxicities over time in order to better understand how they may impact patient experience. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
